BioNTech SE (BNTX) Non-Current Assets (2018 - 2025)
BioNTech SE (BNTX) posted Non-Current Assets of $6.8 billion for Q4 2025, up 5.56% sequentially from $6.4 billion in Q3 2025, and up 70.79% YoY from $4.0 billion in Q4 2024.
BioNTech SE (BNTX) Non-Current Assets (2018 - 2025) Analysis & Trends
BioNTech SE has reported Non-Current Assets for 8 years, with the latest figure at $6.8 billion in Q4 2025.
- Quarterly Non-Current Assets rose 70.79% year-over-year to $6.8 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.5 billion (up 51.46% YoY) and the FY2025 annual result came in at $6.6 billion, up 65.76% from the prior year.
- Non-Current Assets climbed to $6.8 billion in Q4 2025 per BNTX's latest filing, from $6.4 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $6.8 billion in Q4 2025 and troughed at $803.3 million in Q3 2021.
- A 5-year average of $3.2 billion and a median of $3.5 billion in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 224.44% in 2023, then climbed 6.37% in 2024.
- Over 5 years, Non-Current Assets stood at $867.7 million in 2021, then jumped by 59.57% to $1.4 billion in 2022, then surged by 170.35% to $3.7 billion in 2023, then climbed by 6.37% to $4.0 billion in 2024, then soared by 70.79% to $6.8 billion in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $6.8 billion, $6.4 billion, and $6.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 6.80 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.80 Bn |
| Sep 30, 2025 | 6.44 Bn |
| Jun 30, 2025 | 6.46 Bn |
| Mar 31, 2025 | 5.85 Bn |
| Dec 31, 2024 | 3.98 Bn |
| Sep 30, 2024 | 4.30 Bn |
| Jun 30, 2024 | 4.26 Bn |
| Mar 31, 2024 | 4.33 Bn |
| Dec 31, 2023 | 3.74 Bn |
| Sep 30, 2023 | 3.76 Bn |
| Jun 30, 2023 | 3.28 Bn |
| Mar 31, 2023 | 2.14 Bn |
| Dec 31, 2022 | 1.38 Bn |
| Sep 30, 2022 | 1.40 Bn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 935.47 Mn |
| Dec 31, 2021 | 867.70 Mn |
| Sep 30, 2021 | 803.33 Mn |
| Jun 30, 2021 | 854.19 Mn |
| Mar 31, 2021 | 806.61 Mn |